Scope Markets lists OpenAI and Anthropic pre-IPO CFDs at 100% margin: what traders actually buy

A retail customer can now take a price view on OpenAI or Anthropic through Scope Markets without receiving a single share in either company. A 6 November report describes the broker's new MetaTrader 5 pre-IPO contracts for difference, identified by the symbols OPENAI.24_7 and ANTHROPIC.24_7. The products are quoted around the clock, support long and short positions and require margin equal to 100% of the stated position value. The 100% figure means Scope is not advertising borrowing-based leverage on these instruments; it does not make their value fixed or the customer's stake risk-free.[1][2]

The distinction between a CFD and an actual pre-IPO share is the heart of the story. A Scope client holds a bilateral derivative whose value references an indicative private-company price, not registered ordinary shares, an allocation in an eventual offering or the voting and other shareholder rights that stock ownership could confer. An expected flotation can influence the reference value, but the price-setting mechanism, counterparty arrangements and close-out process are broker-contract questions. Public listings are not guaranteed by a product name, and the value implied by a synthetic quote need not be obtainable in a private share sale.[1][2]

The crucial difference between derivatives and pre-IPO shares

The report describes the Scope contracts as referencing indicative prices drawn from pre-IPO derivatives markets. It does not provide independently audited historical price formation, spread data, client execution samples or a verified hedging model. Those are important gaps for anyone using a trading chart to infer a credible company valuation. A 24/7 quote is useful for responding to news outside exchange hours, but the absence of a conventional underlying public order book makes pricing governance particularly important.[1][2]

This structure differs materially from some competitors' offerings. ThinkMarkets announced in October that its own 24/7 pre-IPO markets let traders speculate on the value of OpenAI and Anthropic at the close of the first listing day, and its published announcement emphasised long and short exposure rather than equity ownership. Market reporting on 6 November describes Axi offering related leveraged perpetual contracts with up to 25:1 leverage, and ThinkMarkets products with 10% margin (1:10 leverage), according to ThinkMarkets’ own published product specification. Those are different contract terms from Scope's 100% margin; the same company name on a terminal does not imply the same settlement formula or risk.[1][2]

The right due-diligence questions are exact: which legal entity is the counterparty, what is the reference price and fallback if it stops being published, what happens if a flotation is delayed or cancelled, when can the broker adjust margin or close positions, and which fees apply during continuous quoting? The full product specification should answer these before a trade is placed. Scope's launch is commercially notable, but the available evidence establishes a reported product announcement, not independent verification of its trading performance or a new route to ordinary private equity ownership.[1][2]

Report an error or submit an update